Many South Africans are reportedly encountering difficulty in obtaining their monthly supply of oral contraceptives, a situation emerging as Aspen's East London-based oral contraceptive manufacturing facility was decommissioned in the first quarter of 2026. This has left numerous individuals struggling to secure their essential medication, noting a significant public health concern. Aspen stated that it "took appropriate measures to successfully transition supply containing the same active ingredient to imported branded supply." The company also clarified that "Public sector supply, which constitutes more than 90% of demand, was prioritised and the public sector demands continue to be fully met." Aspen is currently "actively working with SAHPRA to prioritise this application and transfer" for continued supply. For private sector patients, Aspen notes that "In the interim, alternative equivalents are available to the minority of patients in the private sector through retail pharmacy chains and healthcare professionals." The widespread difficulty in obtaining these critical medications has prompted concerns among healthcare providers and patients alike.
Aspen's Manufacturing Shift
The current oral contraceptive shortages in South Africa are directly linked to production disruptions at Aspen Pharmacare. The decommissioning of Aspen's East London-based oral contraceptive manufacturing facility in the first quarter of 2026 has played a significant role in these shortages. This strategic decision by Aspen to cease local production at the East London site has created a vacuum in the supply chain, leading to the current scarcity. Aspen stated it "took appropriate measures to successfully transition supply containing the same active ingredient to imported branded supply." This transition, however, has not been without its challenges, particularly for the private sector.
Aspen emphasized that public sector supply, which constitutes more than 90% of demand, was prioritized. The company confirmed that "Public sector demands continue to be fully met," indicating a focused effort to protect the majority of users who rely on state-provided healthcare. This prioritization was a key part of Aspen's strategy to mitigate the impact of the manufacturing shift. For private sector patients, Aspen noted that "In the interim, alternative equivalents are available to the minority of patients in the private sector through retail pharmacy chains and healthcare professionals." This advice aims to guide those affected towards alternative solutions while the company navigates regulatory processes. Aspen is also "actively working with SAHPRA to prioritise this application and transfer" to ensure continued supply, showing the importance of regulatory approval for imported products. The company's efforts are geared towards ensuring a stable and consistent supply of these essential medications in the long term.
Company Explains Production Issues
Delays in manufacturing at Aspen Pharmacare have led to limited availability of several widely used state-subsidised contraceptives, impacting a significant portion of the population. The problem was reportedly triggered as early as January 2026, setting off a chain of events that resulted in the current scarcity. Aspen addressed the situation, stating it "took appropriate measures to successfully transition supply containing the same active ingredient to imported branded supply." This transition involved a complex process of shifting from local production to reliance on imported sources, which has introduced its own set of logistical and regulatory hurdles. The company emphasized its focus on public health, confirming that "Public sector supply, which constitutes more than 90% of demand, was prioritised and the public sector demands continue to be fully met." This commitment reflects the company's understanding of the critical role these contraceptives play in public health initiatives.
For the private sector, the situation is different as it requires a market authorisation transfer for imported branded products from the South African Health Products Regulatory Authority (SAHPRA). This regulatory step is key for allowing imported medications to be legally sold and distributed within the country's private healthcare system. Aspen clarified, "Aspen is actively working with SAHPRA to prioritise this application and transfer." This process is key for ensuring the continued availability of these imported products to private patients, as without SAHPRA's approval, the supply chain for the private sector remains constrained. Aspen also provided interim guidance for those affected in the private sector, noting, "In the interim, alternative equivalents are available to the minority of patients in the private sector through retail pharmacy chains and healthcare professionals." This indicates that while the regulatory process is underway, other options are accessible to private consumers, though finding suitable alternatives may still pose a challenge for some. The company is actively seeking to expedite the SAHPRA approval process to alleviate the current pressures on private sector supply.
Addressing Patient Needs
The Department of Health has reported limited availability for oral contraceptive products such as Triphasil, Nordette, and Microval at clinics and pharmacies across the country. These specific products are widely used, and their scarcity has created considerable concern among patients and healthcare providers. Aspen Pharmacare has implemented corrective measures to prioritise the supply of certain oral contraceptives to both the local public and private sectors, aiming to mitigate the impact of the shortages. The company stated, "Aspen took appropriate measures to successfully transition supply containing the same active ingredient to imported branded supply." These measures are intended to ensure that essential medications continue to reach those who need them most.
Aspen emphasized its commitment to public health, confirming that "Public sector supply, which constitutes more than 90% of demand, was prioritised and the public sector demands continue to be fully met." This indicates that the majority of patients receiving contraceptives through public health channels should not experience supply disruptions, a testament to the prioritized distribution strategy. This focus on the public sector is vital for maintaining access to contraception for a large segment of the population.
For the private sector, Aspen is actively engaged with regulatory bodies to streamline the introduction of imported products. "Aspen is actively working with SAHPRA to prioritise this application and transfer," the company noted, referring to the key process for obtaining market authorization for imported products. This regulatory hurdle is a significant factor in the current private sector supply issues. In the interim, healthcare retailer and pharmacy Clicks is providing alternatives equivalent to the contraceptives currently in shortage, offering a practical solution for many private patients. Aspen also advised that "In the interim, alternative equivalents are available to the minority of patients in the private sector through retail pharmacy chains and healthcare professionals," further assuring patients that options exist while the long-term supply chain is re-established. The company's proactive steps and collaboration with regulatory bodies and retailers are critical in managing the ongoing challenges and ensuring continued access to these vital medications.
